ChemGenex Pharmaceuticals

Company receives European patent allowance for cancer drug, Quinamed

Published in Law and Health Weekly, March 19th, 2005

ChemGenex announced that it received a notice of allowance from the European Patent Office (EPO) for its patent application entitled "Compositions Containing Naphthalimide and an Antiproliferative Agent."

This patent will cover compositions and methods of use of the company's investigational agent, amonafide (Quinamed), to improve or "chemopotentiate" the anticancer effects of common chemotherapeutics, including cisplatin, paclitaxel, vinblastine, and camptothecin.

Quinamed is currently undergoing phase II human clinical testing as a potential treatment for hormone refractory prostate cancer. Although currently approved antiproliferative agents offer...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2005-03-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry